| 1 |
34702509 | Sensing and imaging of exosomal CD26 secreted from cancer cells and 3D colorectal tumor model using a novel near-infrared fluorogenic probe. | 2021 Nov |
1 |
| 2 |
31640932 | Optimization of the benzamide fragment targeting the S2' site leads to potent dipeptidyl peptidase-IV inhibitors. | 2020 Jan |
4 |
| 3 |
28040864 | GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products. | 2017 Jun |
2 |
| 4 |
28194113 | Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies. | 2017 |
2 |
| 5 |
25482888 | DPP-4 inhibitors: a patent review (2012 - 2014). | 2015 Feb |
2 |
| 6 |
25620096 | Dipeptidyl-peptidase IV (DPP IV/CD26)-activated prodrugs: a successful strategy for improving water solubility and oral bioavailability. | 2015 |
2 |
| 7 |
24056839 | In vitro metabolism of the glucagon-like peptide-1 (GLP-1)-derived metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in mouse and human hepatocytes. | 2013 Dec |
6 |
| 8 |
22307932 | Dipeptidyl peptidase IV (DPPIV/CD26)-based prodrugs of hydroxy-containing drugs. | 2012 Apr |
3 |
| 9 |
22650224 | Non-insulin injectable treatments (glucagon-like peptide-1 and its analogs) and cardiovascular disease. | 2012 Jun |
1 |
| 10 |
23094100 | Allosteric modulation of the activity of the glucagon-like peptide-1 (GLP-1) metabolite GLP-1 9-36 amide at the GLP-1 receptor. | 2012 |
1 |
| 11 |
20018525 | Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. | 2010 Feb |
2 |
| 12 |
20075143 | DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. | 2010 Mar |
1 |
| 13 |
20684603 | Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors. | 2010 Aug 12 |
1 |
| 14 |
21361038 | [Design, synthesis and in vitro activity of glycinamide-bearing compounds as DPP-IV inhibitors]. | 2010 Nov |
2 |
| 15 |
19833514 | The design of potent and selective inhibitors of DPP-4: optimization of ADME properties by amide replacements. | 2009 Nov 15 |
1 |
| 16 |
17904681 | Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects. | 2008 Jan |
1 |
| 17 |
18600568 | From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. | 2008 Jul |
2 |
| 18 |
17675255 | Efficient conversion of tetrapeptide-based TSAO prodrugs to the parent drug by dipeptidyl-peptidase IV (DPPIV/CD26). | 2007 Nov |
1 |
| 19 |
16332437 | Discovery of potent, selective, and orally bioavailable pyridone-based dipeptidyl peptidase-4 inhibitors. | 2006 Mar 1 |
1 |
| 20 |
16913724 | Design and discovery of a novel dipeptidyl-peptidase IV (CD26)-based prodrug approach. | 2006 Aug 24 |
3 |
| 21 |
16919457 | Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors. | 2006 Oct 15 |
1 |
| 22 |
15728907 | Orally active antiviral tripeptide glycyl-prolyl-glycinamide is activated by CD26 (dipeptidyl peptidase IV) before transport across the intestinal epithelium. | 2005 Mar |
2 |
| 23 |
15863311 | Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors. | 2005 May 16 |
1 |
| 24 |
15908206 | Discovery of potent and selective orally bioavailable beta-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors. | 2005 Jun 15 |
1 |
| 25 |
14767880 | Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39). | 2004 Feb |
1 |
| 26 |
15012592 | N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. | 2004 Mar |
2 |
| 27 |
15655705 | Circulation and degradation of GIP and GLP-1. | 2004 Nov-Dec |
1 |
| 28 |
12675225 | Different inhibition mechanisms of dipeptidyl peptidase IV by tryptophan containing peptides and amides. | 2003 |
1 |
| 29 |
14664713 | Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. | 2003 Dec |
1 |
| 30 |
10512614 | NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. | 1999 Sep 7 |
1 |
| 31 |
8798518 | Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach. | 1996 Sep 20 |
1 |
| 32 |
7883856 | Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. | 1995 Mar |
1 |
| 33 |
8100523 | Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. | 1993 Jun 15 |
3 |